|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative)
Datamonitor, Nov 2010, Pages: 276
Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market
While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Avastin, unmet need remains high. Similarly, despite the availability of Herceptin and Tykerb there is also considerable pipeline activity in HER-2-positive breast cancer. At the same time, there is uncertainty over the optimal way of using Herceptin and Tykerb in this patient subset.
Features and benefits
- Analysis of the hormone receptor-negative breast cancer market based on a survey of 180 specialists, supported by opinion leader interviews
- Epidemiological forecasts of breast cancer incidence and prevalence for the period 2010–19 in the seven major pharmaceutical markets
- Segmentation of incident cases by age group, menopausal status, stage of disease and subtype
- In-depth analysis of treatment patterns and regimens prescribed for TNBC and HER-2-positive breast cancer by line of therapy and disease stage
Highlights
Herceptin (trastuzumab; Roche/Chugai) has established a formidable position in the HER-2-positive breast cancer market. At relapse, retreatment with an alternative Herceptin-based regimen is favored over switching to Tykerb (lapatinib; GlaxoSmithKline), reflecting the lack of clinical data showing that switching to Tykerb is beneficial.
Avastin (bevacizumab; Roche/Chugai) has captured considerable market share in first-line metastatic TNBC in the US; loss of this indication would therefore have a large impact on sales. Avastin is also vulnerable to competition from new market entrants (e.g. Sanofi Aventis’s iniparib), even if it retains its breast cancer indication.
The popularity of Xeloda (capecitabine; Roche/Chugai) shows that side-effect profile is an important driver of prescribing behavior in metastatic TNBC beyond the first-line of therapy. It is therefore critical that new market entrants in this setting are well tolerated if they are to achieve extensive uptake.
Your key questions answered
- Validate new product forecasting based on epidemiology, patient segmentation and treatment rates, and the likely rate of uptake for new products
- Understand prescribing trends and identify key factors that influence treatment choices in defined breast cancer populations
- Enhance commercial positioning by increasing understanding of current dynamics within the breast cancer market
Customers who bought this item also bought
US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer
Triple Positive Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey
Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer: US Oncologist Survey
Optimizing Treatment for Bone Metastases in Advanced Cancers 2011
Triple Negative Metastatic Breast Cancer: Clinical Insights from a US Oncologists Survey
Herceptin (Breast Cancer) - Analysis and Forecasts to 2020
The Cancer Market Outlook to 2016
Tykerb (Breast Cancer) - Analysis and Forecasts to 2020
Stakeholder Insight: Gastric Cancer
Thought Leader Insight & Analysis Report - Breast Cancer Q1 2010
|
|
|
|
